RCUS Q1 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+38.9% YoY

Gross Profit

$25M100.0% margin

Operating Income

-$86M-344.0% margin

Net Income

-$80M-320.0% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-25.7%

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$101M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$654M

Stockholders' Equity

$600M

Cash & Equivalents

$238M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$18M	+38.9%
Gross Profit	$25M	$18M	+38.9%
Operating Income	-$86M	-$67M	-28.4%
Net Income	-$80M	-$68M	-17.6%

Revenue Segments

License and Development Services Revenue

$17M68%

Other Collaboration Revenue

$8M32%